Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Getting Companies To Discuss Their Pediatric Research Plans Early: EMA Pilot Finally Gets Off To A Start

This article was originally published in SRA

Executive Summary

Interest is finally to beginning to pick up in the European Medicines Agency's pilot project on offering early scientific advice to drug sponsors to support the development of pediatric medicines. The pilot had initially drawn a lukewarm response from pharmaceutical companies, who showed reluctance to discuss their pediatric research plans with the agency at an early stage.

You may also be interested in...



Parallel EMA-FDA Pediatric Advice On The Cards For Companies

The European Medicines Agency is working on plans to supplement its early advice pilot on pediatric development by providing joint advice with the US FDA and, in some cases, by arranging for a three-way dialogue with companies.

Simplified Clinical Trial Transparency Rules To Go Live In The EU In June

A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules. 

WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency

The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS118414

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel